未登录 分享 收藏
分享 收藏
分享 收藏
Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes Hwang, Inwoo; Lim, Yoojoo; Song, Sanghoon; Lee, Hyunwoo; Cho, Yoon Ah; Im, Young-Hyuck; An, Jin Seok; Park, Yeon Hee; Kim, Ji-Yeon; Cho, Eun Yoon 分享 收藏
分享 收藏
Pembrolizumab plus Olaparib vs Pembrolizumab plus Chemotherapy After Induction With Pembrolizumab plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study Rugo, Hope; Robson, Mark; Im, Seock-Ah; Dalenc, Florence; Ruiz, Eduardo Yanez; Im, Young-Hyuck; Kulyk, Sergii; Dudnichenko, Oleksandr; Llinas-Quintero, Nestor; Saji, Shigehira; Miyoshi, Yasuo; Harbeck, Nadia; Fan, Li; Mejia, Jaime; Karantza, Vassiliki; Cescon, David 分享 收藏
Gene expression signature as a predictor of pathological complete response to neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab treatment in locally advanced HER2-positive breast cancer Shin, Junghoon; Kim, Ji-Yeon; Cho, Eun Yoon; Kim, Seok Won; Lee, Jeong Eon; Lee, Hyunwoo; Park, Yeon Hee; Ahn, Jin Seok; Im, Young-Hyuck 分享 收藏
Prognostication of genomic characteristics of residual breast cancer after neoadjuvant chemotherapy Kim, Ji-Yeon; Park, Sabin; Ahn, Sepil; Seo, Eun Seop; Kim, Soyeon; Gregory, Mark; Killingbeck, Emily; Cho, Eun Yoon; Lee, Jeong Eon; Ahn, Jin Seok; Park, Yeon Hee; Park, Woong-Yang; Kim, Hoon; Lee, Semin; Im, Young-Hyuck 分享 收藏
分享 收藏
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/ pertuzumab for HER2-positive breast cancer Kim, Nalee; Kim, Ji-Yeon; Park, Won; Cho, Won Kyung; Kim, Tae Gyu; Im, Young-Hyuck; Ahn, Jin Seok; Lee, Jeong Eon; Nam, Seok Jin; Kim, Seok Won; Yu, Jonghan; Chae, Byung Joo; Lee, Sei Kyung; Ryu, Jai -Min; Park, Yeon Hee; Kim, Haeyoung 分享 收藏
分享 收藏
Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer Kim, Ji-Yeon; Park, Sabin; Cho, Eun Yoon; Lee, Jeong Eon; Jung, Hae Hyun; Chae, Byung Joo; Kim, Seok Won; Nam, Seok Jin; Cho, Soo Youn; Park, Yeon Hee; Ahn, Jin Seok; Lee, Semin; Im, Young-Hyuck 分享 收藏
ER+, HER2-advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes Chen, Jessica W.; Jacot, William; Cortes, Javier; Krop, Ian E.; Dent, Susan; Harbeck, Nadia; De Laurentiis, Michelino; Dieras, Veronique; Im, Young-Hyuck; Stout, Thomas J.; Schimmoller, Frauke; Savage, Heidi M.; Hutchinson, Katherine E.; Wilson, Timothy R. 分享 收藏
分享 收藏
分享 收藏
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1) Imoto, Shigeru; Wang, Kun; Bi, Xi-wen; Liu, Guangyu; Im, Young-Hyuck; Im, Seock-Ah; Sim, Sung Hoon; Ueno, Takayuki; Futamura, Manabu; Toi, Masakazu; Fujiwara, Yasuhiro; Ahn, Sung Gwe; Lee, Jeong Eon; Park, Yeon Hee; Takao, Shintaro; Oba, Mari Saito; Kitagawa, Yuko; Nishiyama, Masahiko 分享 收藏
Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy Kim, Ji-Yeon; Oh, Jung Min; Lee, Se Kyung; Yu, Jonghan; Lee, Jeong Eon; Kim, Seok Won; Nam, Seok Jin; Park, Yeon Hee; Ahn, Jin Seok; Kim, Kyunga; Im, Young-Hyuck 分享 收藏
Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1 Toi, M.; Boyle, F.; Im, Y. -H.; Reinisch, M.; Molthrop, D.; Jiang, Z.; Wei, R. J.; Sapunar, F.; Grimes, B.; Nabinger, S. C.; Johnston, S. R. D. 分享 收藏
Correlation between work productivity loss and EORTC QLQ-C30 and-BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2-advanced breast cancer Tripathy, Debu; Curteis, Tristan; Hurvitz, Sara; Yardley, Denise; Franke, Fabio; Babu, K. Govind; Wheatley-Price, Paul; Im, Young-Hyuck; Pencheva, Radost; Eddowes, Lucy A.; Dionne, Pierre-Alexandre; Chandiwana, David; Pathak, Purnima; Lanoue, Brad; Harbeck, Nadia 分享 收藏
Identification of PD-L1+status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study Rugo, Hope S.; Blum, Joanne L.; Laird, A. Douglas; Hurvitz, Sara A.; Ettl, Johannes; Mina, Lida A.; Lee, Kyung-Hun; Goncalves, Anthony; Yerushalmi, Rinat; Im, Young-Hyuck; Martin, Miguel; Fehrenbacher, Louis; Roche, Henri H.; Chen, Ying; Lanzalone, Silvana; Chelliserry, Jijumon; Eiermann, Wolfgang; Litton, Jennifer K. 分享 收藏